NEULANDLAB.NS Balance Sheet
Neuland Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 23:40
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹457.43 Cr. | ₹522.72 Cr. | ₹673.71 Cr. | ₹892.29 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹40.57 Cr. | ₹45.89 Cr. | ₹44.55 Cr. | ₹209.50 Cr. | CapitalWorkInProgress |
| Goodwill | ₹279.46 Cr. | ₹279.46 Cr. | ₹279.46 Cr. | ₹279.46 Cr. | Goodwill |
| Other Intangible Assets | ₹1.30 Cr. | ₹2.46 Cr. | ₹1.74 Cr. | ₹5.18 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹0.52 Cr. | ₹1.28 Cr. | ₹1.53 Cr. | ₹1.98 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹12.52 Cr. | ₹32.18 Cr. | ₹15.60 Cr. | ₹45.57 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹818.87 Cr. | ₹911.48 Cr. | ₹1,040.38 Cr. | ₹1,447.01 Cr. | NoncurrentAssets |
| Inventories | ₹279.23 Cr. | ₹350.42 Cr. | ₹385.76 Cr. | ₹510.29 Cr. | Inventories |
| Trade Receivables | ₹361.77 Cr. | ₹373.53 Cr. | ₹315.72 Cr. | ₹541.35 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹45.42 Cr. | ₹87.58 Cr. | ₹131.93 Cr. | ₹76.67 Cr. | CashAndCashEquivalents |
| Current Investments | ₹0.00 Cr. | ₹0.00 Cr. | ₹107.68 Cr. | ₹0.00 Cr. | CurrentInvestments |
| Other Current Assets | ₹53.76 Cr. | ₹77.45 Cr. | ₹69.30 Cr. | ₹72.19 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹760.89 Cr. | ₹921.08 Cr. | ₹1,139.50 Cr. | ₹1,483.13 Cr. | CurrentAssets |
| Total Assets | ₹1,579.76 Cr. | ₹1,832.56 Cr. | ₹2,179.88 Cr. | ₹2,930.14 Cr. | Assets |
| Equity Share Capital | ₹12.90 Cr. | ₹12.90 Cr. | ₹12.90 Cr. | ₹12.90 Cr. | EquityShareCapital |
| Other Equity | ₹981.20 Cr. | ₹1,269.80 Cr. | ₹1,511.91 Cr. | ₹1,861.57 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹994.10 Cr. | ₹1,282.70 Cr. | ₹1,524.81 Cr. | ₹1,874.47 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | N/A | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | NonControllingInterest |
| Total Equity | ₹994.10 Cr. | ₹1,282.70 Cr. | ₹1,524.81 Cr. | ₹1,874.47 Cr. | Equity |
| Long-term Borrowings | ₹74.25 Cr. | ₹44.92 Cr. | ₹90.73 Cr. | ₹160.95 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹146.71 Cr. | ₹122.17 Cr. | ₹189.39 Cr. | ₹345.47 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹47.26 Cr. | ₹37.59 Cr. | ₹45.28 Cr. | ₹35.67 Cr. | BorrowingsCurrent |
| Trade Payables | ₹171.01 Cr. | ₹191.96 Cr. | ₹252.20 Cr. | ₹269.14 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹140.12 Cr. | ₹86.14 Cr. | ₹78.96 Cr. | ₹253.18 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹438.96 Cr. | ₹427.68 Cr. | ₹465.69 Cr. | ₹710.20 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹1,579.76 Cr. | ₹1,832.56 Cr. | ₹2,179.88 Cr. | ₹2,930.14 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from NEULANDLAB.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).